Conditions: Diabetes Mellitus, Type 2 Atherosclerosis Prediabetic State
Keywords: Atherosclerosis, Type 2 Diabetes Mellitus, T2DM, Cardiovascular Diseases, ACZ885, impaired glucose tolerance, IGT, Canakinumab
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 189
Healthy volunteers: no

Brief summary:
This study will evaluate the effect of ACZ885 on vascular function in patients with documented atherosclerotic disease and T2DM or IGT.

Detailed description:

Arms:
arm 1: subcutaneous (SQ) monthly arm 2: 150 mg SQ monthly

Interventions: intervention 1: ACZ885 intervention 2: Placebo
Intervention descriptions: intervention 1: ACZ885 150 mg was administered subcutaneously once a month for 12 months. intervention 2: Matching placebo to ACZ885 was administered subcutaneously once a month for 12 months.

Protocol document: